Skip to main content
. 2023 Dec 7;14:1302307. doi: 10.3389/fimmu.2023.1302307

Figure 2.

Figure 2

A detailed timeline of CAR-T therapy development from the laboratory bench to the approval of several products by the US FDA for medical use. B-ALL, B-cell acute lymphoblastic leukemia; DLBCL, diffuse large B-cell lymphoma; FDA, Food and Drug Administration; FL, follicular lymphoma; MCL, mantel cell lymphoma; MM, multiple myeloma; MSKCC, Memorial Sloan Kettering Cancer Center; NCI, National Cancer Institute; UPenn, University of Pennsylvania.